TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
946.53M	884.09M	882.85M	802.54M	366.78M	104.80M
	Gross Profit
633.24M	597.90M	612.88M	531.52M	265.94M	88.36M
	EBIT
142.28M	144.32M	189.15M	162.54M	88.75M	19.97M
	EBITDA
199.84M	224.29M	324.53M	271.30M	115.05M	30.22M
	Net Income Common Stockholders
141.09M	131.65M	233.97M	187.97M	86.25M	15.61M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
612.89M	968.15M	634.37M	433.73M	316.68M	87.16M
	Total Assets
4.90B	5.48B	4.70B	4.65B	3.98B	472.27M
	Total Debt
1.64M	292.35M	40.02M	14.68M	12.07M	2.32M
	Net Debt
-611.25M	-675.81M	-594.34M	-419.05M	-304.61M	-84.84M
	Total Liabilities
420.50M	651.03M	357.46M	413.11M	393.06M	45.22M
	Stockholders Equity
4.48B	4.83B	4.35B	4.24B	3.59B	427.05M
Cash Flow		Free Cash Flow
55.95M	89.69M	194.16M	94.94M	24.71M	14.53M
	Operating Cash Flow
103.78M	137.22M	238.29M	129.49M	39.08M	23.23M
	Investing Cash Flow
-132.71M	-47.53M	-44.13M	-34.55M	-2.73B	-8.69M
	Financing Cash Flow
-4.29M	227.65M	15.85M	17.09M	2.92B	4.21M

Surgical Science Sweden AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUS		kr7.75B	54.90		―	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
CLVSF		$479.85M	28.09	18.49%	1.38%	―	―
PXMBF		$165.16M	32.96	10.01%	―	―	―
SNZZF		$71.68M	―	-37.17%	―	―	―
24C		€104.66M	35.92	10.11%	―	―	―
6Y4		€199.65M	―	-40.15%	―	―	―

* Healthcare Sector Average

Performance Comparison

SE:SUS

Surgical Science Sweden AB

151.80

12.90

9.29%

CLVSF

CellaVision AB

16.82

-7.95

-32.10%

PXMBF

Paxman AB

3.50

0.00

0.00%

SNZZF

Senzime AB

0.52

-0.17

-24.64%

DE:24C

C-Rad AB Class B

2.98

-0.84

-21.99%

DE:6Y4

Vicore Pharma Holding AB

0.84

-1.04

-55.32%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.